# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Susan B. Anthony (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI014-SYN
- Date: 2026-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harold Pemberton, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for primary care visit for breathlessness on exertion and ankle swelling. **S**

## Objective

NT-proBNP: 1650 pg/mL (high); Sodium: 138 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.88 mg/dL; eGFR: 64 mL/min/1.73 m²; Glucose: 96 mg/dL; Magnesium: 2 mg/dL; Hemoglobin: 12.4 g/dL; Ferritin: 140 ng/mL; Transferrin saturation: 24%; TSH: 2.4 mIU/L; HbA1c: 5.5%; LDL cholesterol: 96 mg/dL; ALT: 18 U/L; KCCQ-12 overall summary: 52; PHQ-2: 0. All results are synthetic.

BP 158/86 mmHg; pulse 84 bpm; respirations 20/min; temperature 36.7 °C; oxygen saturation 95% on room air; weight 58.5 kg; BMI 21.5 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Heart failure with preserved ejection fraction, NYHA class II to III at diagnosis; synthetic modern diagnosis linked to the documented 1906 heart failure; Hypertensive heart disease with heart failure. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Furosemide 20 mg oral tablet, one tablet by mouth daily **S**
- Started: Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**

## Plan

- Treat congestion with furosemide and start empagliflozin for HFpEF; move to as-needed furosemide guided by daily weights once euvolemic. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023) **S**
- Add low-dose spironolactone for HFpEF with blood pressure above target once potassium and kidney function are stable. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023) **S**
- Cardiology referral to confirm the diagnosis, review the echocardiogram, and look for specific causes such as amyloidosis or valve disease. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023) **S**
- Check a basic metabolic panel and magnesium one to two weeks after starting or changing diuretic, SGLT2 inhibitor, or mineralocorticoid antagonist therapy, then every three to six months; KCCQ-12 every three to six months. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026) **S**
- Daily weights, sodium moderation, a written travel plan for weight gain, and continued daily walking; refer to cardiac rehabilitation if exercise tolerance plateaus. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026) **S**
- Pneumococcal and RSV vaccination and a yearly high-dose influenza vaccine to lower the risk of respiratory infection in heart failure. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026) **S**
